Related Experiment Video

Updated: May 23, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Sex-Based Disparities in Fabry Disease Cause Challenges in Newborn Screening

Yutaka Furuta1, Neena S Agrawal2, Natalie N Owen2

  • 1Department of Pediatrics, Division of Medical Genetics and Genomic Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA, yutakafuruta8@gmail.com.

Public Health Genomics
|May 21, 2026
PubMed

Insights

Newborn screening for Fabry disease (FD) misses most females due to higher residual enzyme activity. This leads to delayed diagnosis and treatment for affected females compared to males.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Fabry disease (FD) is an X-linked lysosomal storage disorder impacting multiple systems.
  • Decreased alpha-galactosidase activity is the primary cause of FD.
  • Current newborn screening (NBS) methods may not effectively detect affected females.

Purpose of the Study:

  • To investigate sex-based diagnostic disparities in Fabry disease.
  • To understand how limitations in enzyme-based newborn screening affect female diagnosis.
  • To identify potential improvements for early detection in females.

Main Methods:

  • Retrospective analysis of Fabry Registry and Tennessee NBS data (2001-2024).
  • Comparison of sex differences in diagnosis, biochemical phenotype, symptom onset, and treatment initiation.
  • Statistical analysis using Wilcoxon and Chi-square tests.

Main Results:

  • Enzyme-based NBS identified 73 individuals (67 males, 6 females) from the Fabry Registry.
  • Affected females exhibited significantly higher residual alpha-galactosidase activity than males.
  • Females experienced delayed symptom onset, diagnosis, and lower treatment rates compared to males.

Conclusions:

  • Females with Fabry disease face delays in symptom onset, diagnosis, and treatment.
  • Current enzyme-based NBS misses most affected females due to higher residual enzyme activity.
  • Implementing sex-specific cutoffs or molecular sequencing in NBS can enhance early detection and reduce disparities.
Abstract

Keywords:
Fabry diseaseNewborn screeningPublic healthSex-based disparitiesα-Galactosidase

More Related Videos

Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 105:44

Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 1

Published on: May 17, 2024

Related Concept Videos

Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
Pedigree Analysis01:35

Pedigree Analysis

Overview
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
X-linked Traits01:19

X-linked Traits

In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.